Company News

- Read more about Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Sanofi and GSK announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
- Read more about First Made in India COVID-19 tests kit by Mylab gets commercial approval from CDSCO
- Read more about AbbVie to determine efficacy of Lopinavir and Ritonavir for treatment of COVID-19
AbbVie confirmed the company's activities in the fight to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Kaletra/Aluvia (lopinavir/ritonavir) to determine its efficacy in the treatment of COVID-19.
- Read more about Aurobindo Pharma received OAI letter from FDA
Aurobindo Pharma received Official Action Indicated letter from USFDA after inspection in october 2019.
- Read more about Sun Pharma to defend antitrust claims in USA
Sun Pharma along with its wholly owned subsidiaries is a defendant in a multi-district litigation brought by various classes of plaintiffs, in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs which are Valganciclovir, Valsartan and Esomeprazole.
- Read more about Pharma companies received notices for introducing drugs without prior approval of the NPPA
Pharmaceutical Companies which introduced 22 drugs without prior approval of the National Pharmaceutical Pricing Authority (NPPA) have been issued notices by Government. The NPPA regularly takes action against such companies as per provisions of the Drugs (Prices Control) Order, 2013 (DPCO) which has been issued under the Essential Commodities Act, 1955.
- Read more about Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
Sanofi and Regeneron Pharmaceuticals, Inc. announced that a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo. The trial also met a key secondary endpoint, demonstrating REGN3500 monotherapy significantly improved lung function compared to placebo.
- Read more about Pfizer to shut its Chennai and Aurangabad plants
Pfizer Healthcare India Pvt Ltd, a subsidiary of Pfizer Inc., USA to shut down its two Indian plants located in Chennai and Aurangabad. These both plants are part of its international acquisition of Hospira in 2015.
- Read more about MacroGenics announced the presentation of clinical data from its ongoing Phase 1 study of flotetuzumab in an oral session at the American Society of Hematology
MacroGenics, Inc a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced the presentation of clinical data from its ongoing Phase 1 study of flotetuzumab in an oral session at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. John E. Godwin, M.D., Program Leader, Hematologic Malignancies at Earle A. Chiles Research Institute at Providence Cancer Center in Portland, Oregon presented "Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific DART Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome."
- Read more about Insulin degludec lead to lesser hypoglycemia in compare to Insulin Glargine : Finding
People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation (IDF) Annual Congress in Abu Dhabi.